Mésothéliome

TITRE	(EN) A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma
PROTOCOLE ID	eVOLVE-Meso
CLINICAL TRIAL.gov ID	NCT06097728
TYPE(S) DE CANCER	Mésothéliome
PHASE	Phase III
TYPE D'ÉTUDE	Clinique
INSTITUTION	INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE 272, chemin Sainte-Foy (418) 656-8711
VILLE	Québec
INVESTIGATEUR(RICE) PRINCIPAL(E)	Catherine Labbé
COORDONATEUR(RICE)	Brigitte Fortin brigitte.fortin@criucpq.ulaval.ca 418-656-8711 poste 2639
STATUT	Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ	(EN) Participant must be ≥ 18 years at the time of screening Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid) Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy) WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS>1) over the previous 2 weeks prior to day of first dosing Has measurable disease per modified RECIST1.1 Has adequate bone marrow reserve and organ function at baseline
CRITÈRES D'EXCLUSION	(EN) As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results. Active or prior documented autoimmune or inflammatory disorders History of another primary malignancy with exceptions. Uncontrolled intercurrent illness Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment Untreated or progressive CNS metastatic disease